Advertisement

Pharmacokinetics and Safety of Levetiracetam Extended-Release Tablets and Relative Bioavailability Compared with Immediate-Release Tablets in Healthy Chinese Subjects

  • Meng Wang
  • Mengmeng Wang
  • Quanying Zhang
  • Shunlin Zong
  • Chengzhe LvEmail author
Original Research Article
  • 130 Downloads

Abstract

Background and Objectives

Levetiracetam is a second-generation antiepileptic drug and distributed ubiquitously in the central nervous system. The extended-release formulation of levetiracetam was developed to provide patients with the convenience of once-daily dosing, to improve drug compliance and tolerability. The objective of this study was to evaluate the pharmacokinetics and safety of levetiracetam extended-release (ER) tablets in healthy Chinese subjects following single and multiple doses.

Methods

Two panels of 34 healthy subjects were enrolled. Trial 1 was a two-way crossover between levetiracetam ER tablets and immediate-release (IR) tablets under fasting conditions. Trial 2 was a four-way crossover single-dose study between levetiracetam ER fasted and ER with food.

Results

Intake of single and multiple levetiracetam ER tablets resulted in a 42.3% lower maximum plasma concentration (Cmax) and a 33.6% lower minimum steady-state plasma concentration (Css min) than IR tablet intake, while the median time to Cmax (tmax) was significantly delayed. The 90% CI of the ER/IR ratios for area under the curve (AUC) from zero to last measurable sample (AUC0–t), AUC from zero to infinity (AUC0–), AUC at steady state (AUCss, τ = 24 h), Cmax at steady state (Css max) and average concentration at steady state (Css av) were contained within the 80–125% range of bioequivalence. The Cmax and AUC were dose proportional across the dose cohorts. Following a high-fat meal, levetiracetam ER tablets resulted in a 14.4% higher Cmax. The 90% confidence interval (CIs) of the fed/fasted ratios for Cmax and AUC were entirely contained within the 80–125% range of bioequivalence acceptance, except the tmax was delayed (P < 0.05). The most frequent treatment-emergent adverse events were somnolence, dizziness and thirst.

Conclusions

After single and multiple doses, the absorption of levetiracetam ER was equal to IR, the tmax was significantly delayed, and the Cmax and Css min were significantly decreased. Food did not affect the absorption of the levetiracetam ER tablet, but the Cmax increased and the tmax was delayed. The levetiracetam ER tablet was well tolerated and found to be dose proportional from 500 to 2000 mg in healthy Chinese subjects.

Notes

Acknowledgements

The authors thank all of the subjects enrolled in this study. We also thank the staff of the clinical ward and bioanalytical lab of Clinical Pharmacology Laboratory in the Second Affiliated Hospital of Soochow University (Suzhou, China). The authors acknowledge Dr. Michael Van Meter for the assistances in writing the manuscript.

Compliance with Ethical Standards

Funding

The study was supported by Hunan pharmaceutical company (Changde, China).

Conflict of interest

Meng Wang, Mengmeng Wang, Quanying Zhang, Shunlin Zong, and Chengzhe Lv declare no conflict of interest.

Ethical approval

Study protocols and the informed consent forms were approved by the independent ethics committee of the Second Affiliated Hospital of Soochow University (Suzhou, China).

Informed consent

Subjects provided written informed consent before study participation.

References

  1. 1.
    Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia. 1975;16:1–66.CrossRefPubMedGoogle Scholar
  2. 2.
    Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia. 1993;34:453–68.CrossRefPubMedGoogle Scholar
  3. 3.
    Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101:9861–6.CrossRefPubMedGoogle Scholar
  4. 4.
    AbouKhalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2008;4:507–23.CrossRefGoogle Scholar
  5. 5.
    Noyer M, Gillard M, Matagne A, Hénichart JP, Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 1995;286:137–46.CrossRefPubMedGoogle Scholar
  6. 6.
    Sohn YH, Jung HY, Kaelin-Lang A, Hallett M. Effect of levetiracetam on rapid motor learning in humans. Arch Neurol. 2002;59:1909–12.CrossRefPubMedGoogle Scholar
  7. 7.
    Ulloa CM, Towfigh A, Safdieh J. Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. Neuropsychiatr Dis Treat. 2009;5:467–76.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Peltola J, Coetzee C, Jiménez F, Litovchenko T, Ramaratnam S, Zaslavaskiy L, Lu ZS, Sykes DM. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Epilepsia. 2009;50:406–14.CrossRefPubMedGoogle Scholar
  9. 9.
    Rouits E, Burton I, Guénolé E, Troenaru MM, Stockis A, Sargentini-Maier ML. Pharmacokinetics of levetiracetam ER 500 mg tablets. Epilepsy Res. 2009;84:224–31.CrossRefPubMedGoogle Scholar
  10. 10.
    Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77–85.CrossRefPubMedGoogle Scholar
  11. 11.
    Sun RY, Cheng ZY, Zheng QS. Drug and statistics software (DAS). Am J Pharm Educ. 2005;69(3):397–8.Google Scholar
  12. 12.
    Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat. 2009;8:38–49.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhao Q, Jiang J, Li XM, Lu Z, Hu P. Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. Br J Clin Pharmacol. 2007;63(5):614–7.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Boozer LB, Platt SR, Haley AC, Linville AV, Kent M, Barron LE, Nie B, Arnold RD. Pharmacokinetic evaluation of immediate- and extended-release formulations of levetiracetam in dogs. Am J Vet Res. 2015;76:719–23.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Meng Wang
    • 1
  • Mengmeng Wang
    • 1
  • Quanying Zhang
    • 1
  • Shunlin Zong
    • 1
  • Chengzhe Lv
    • 2
    Email author
  1. 1.Clinical Pharmacology LaboratoryThe Second Affiliated Hospital of Soochow UniversitySuzhouChina
  2. 2.Department of PharmaceuticsChildren’s Hospital of Soochow UniversitySuzhouChina

Personalised recommendations